Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.57 |
| ▸ | CTSS | P25774 | 6/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | PPARA | Q07869 | 6/20 | 0.52 |
| ▸ | PPARG | P37231 | 5/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908039 | 1.00 | ACE (0.57) | ACECTSSCTSKPPARAPPARG | |
| SCHEMBL1350266 | 1.00 | ACE (0.57) | ACECTSSCTSKPPARAPPARG | |
| SCHEMBL3485116 | 1.00 | ACE (0.57) | ACECTSSCTSKPPARAPPARG | |
| SCHEMBL30962391 | 0.90 | CTSS (0.53) | ACECTSSCTSKPPARAPPARG | |
| SCHEMBL25270309 | 0.88 | KLK5 (0.52) | ACECTSSCTSKSCN9ASCN10A | |
| SCHEMBL25217471 | 0.88 | KLK5 (0.52) | ACECTSSCTSKSCN9ASCN10A | |
| SCHEMBL22287759 | 0.88 | CTSS (0.53) | ACECTSSCTSKPPARAPPARG | |
| SCHEMBL22287760 | 0.88 | CTSS (0.53) | ACECTSSCTSKPPARAPPARG | |
| SCHEMBL1336069 | 0.87 | CTSK (0.55) | ACECTSSCTSKPPARAPPARG | |
| SCHEMBL6123222 | 0.87 | SCN9A (0.59) | ACECTSSCTSKPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104910046-B | Phenylacetylene derivative with double chiral carbon atoms on pendant group and preparation method and application thereof | 哈尔滨工程大学 | 2017-05-24 | — | — | CN | claimed |
| CN-104910039-A | Functional phenylacetylene compound and preparation method thereof | UNIV HARBIN ENG | 2015-09-16 | — | — | CN | claimed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20240057599-A1 | METHODS FOR IMPROVING FRUIT QUALITY | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2024-02-22 | — | — | US | disclosed |
| CN-117529476-A | Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments | 亚飞络思制药公司 | 2024-02-06 | — | — | CN | disclosed |
| US-11812746-B2 | Method of controlling fungal infections in plants | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2023-11-14 | — | — | US | disclosed |
| CN-116323596-A | Interleukin-17 inhibitors | 诺华股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023107597-A2 | BICYCLIC HETEROAROMATIC AMIDE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11377425-B1 | Small molecule modulators of IL-17 | LEO PHARMA A/S (DK) | 2022-07-05 | — | — | US | disclosed |
| US-11377425-B1 | Small molecule modulators of IL-17 | LEO PHARMA A/S (DK) | 2022-07-05 | — | — | US | disclosed |
| EP-0719251-B1 | BICYCLO (2.2.2) OCTANE DERIVATIVES CHOLECYSTOKININ AND/OR GASTRIN ANTAGONISTS | BLACK JAMES FOUNDATION (GB) | 1998-12-09 | — | — | EP | disclosed |
| EP-0866705-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-09-30 | — | — | EP | disclosed |
| US-5795907-A | Gastin and CCK receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-08-18 | — | — | US | disclosed |
| WO-1997014417-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-04-24 | — | — | WO | disclosed |
| EP-0720601-A1 | GASTRIN AND CCK RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-07-10 | — | — | EP | disclosed |
| EP-0719251-A1 | BICYCLO (2.2.2) OCTANE DERIVATIVES CHOLECYSTOKININ AND/OR GASTRIN ANTAGONISTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-07-03 | — | — | EP | disclosed |
| US-5514683-A | LIGANDS FKOR CHOLECYSTOKININ OR GASTRIN RECEPTORS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-05-07 | — | — | US | disclosed |
| WO-1995005359-A1 | BICYCLO (2.2.2) OCTANE DERIVATIVES CHOLECYSTOKININ AND/OR GASTRIN ANTAGONISTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
| WO-1995004720-A2 | GASTRIN AND CCK RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377425-B1 | Small molecule modulators of IL-17 | IL17A, IL15, IL2 | ACE 2028/4885CTSS 757/4885CTSK 441/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | ACE 1944/4885CTSS 4022/4885CTSK 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.